Loading stock data…
PRF Technologies Ltd. (PRFX)
$1.41-0.10 (-6.62%)
After Hours$1.44+0.03 (+2.06%)· Last close Jun 29
PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
PRF Technologies Ltd. in the Healthcare sector is trading at $1.41 with a market capitalization of $4M. The stock is currently near its 52-week low of $1.28, remaining 62.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q4 2025 | Q2 2025 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|
| Total Revenue | — | — | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | -$7.34M↓ | -$5.57M↓ | -$3.56M |
| Net Income | — | — | -$7.31M↓ | -$5.51M↓ | -$4.89M |
Peer Comparison
JNJUNHPFE
Fundamentals
PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in catarac...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.29M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.98
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-206.87%
Volume
Today's trading volume
331,214
Recent News
Sector Update: Healthcare Stocks Gain Late Afternoon
Healthcare stocks rose late Thursday afternoon with the NYSE Healthcare Index gaining 1.7% and the S
Top Premarket Gainers
PRF Technologies (PRFX) shares were up over 250% in Friday premarket activity after the company upda
EXCLUSIVE: PRF Technologies Advances Drop-Less Drug For Cataract Surgery Pain
The U.S. Food and Drug Administration (FDA) on Tuesday cleared PRF Technologies Ltd.'s Investigational New Drug application for OcuRing-K, enabling the company to move into a Phase 2 trial targeting pain and inflammation following cataract surgery. The milestone advances PRF's strategy to develop a sustained-release, drop-less therapy aimed at simplifying post-operative care. The company is focused on the reformulation of established therapeutics and developing AI-driven energy optimization tech
BC-Most Active Stocks
Gibo Holdings Ltd. 62,940,523 0.0274